Intravitreal ranibizumab injection for the treatment of large submacular hemorrhage Due to neovascular age-related macular degeneration

Details

Serval ID
serval:BIB_A1F43AAC31E8
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
Intravitreal ranibizumab injection for the treatment of large submacular hemorrhage Due to neovascular age-related macular degeneration
Title of the conference
Ophta 2010
Author(s)
Konstantinidis Lazaros
Organization
103e Congrès annuel de la Société Suisse d’Ophtalmologie
Address
Montreux Music & Convention Center MMCC
Grand-Rue 95,
P.O. Box 1151,
CH-1820 Montreux
Publication state
Published
Issued date
19/09/2010
Pages
S68
Language
english
Notes
Poster session 3: Retina II
Abstract
Predominantly hemorrhagic neovascular age-related macular degeneration (AMD) has a very poor natural history, lead- ing to severe visual loss. Patients and Methods Retrospective study of patients with predominantly hemorrhagic AMD treated with intravitreal ranibizumab at the Jules Gonin Eye Hospital between December 2006 and December 2008. Baseline and monthly follow- up exams included visual acuity (VA), fundus exam and optical coherence tomography while fluorescein and indocyanine green angiography were performed at least every three months. Results The study included 8 eyes. Mean follow-up was 13 months (SD: 6.3). The mean number of intravitreal injections administered for each patient was 6.4 (SD: 2). 63% of the patients demonstrated stable or improved VA. The size of hemorrhage at baseline was inversely correlated to the final VA (P: 0.038) and positively corre- lated to the final central macular thickness (P: 0.021). Anticoagula- tion treatment was inversely correlated to the time of hemorrhage resolution (P: 0.039). Conclusions Intravitreal ranibizumab should be considered as a therapeutic option for predominantly hemor- rhagic lesions due to neovascular AMD.
Create date
06/09/2019 12:08
Last modification date
07/09/2019 5:26
Usage data